Anthem Biosciences Limited is one of India’s top innovation-driven Contract Research, Development and Manufacturing Organizations (CRDMO) set to launch its IPO. The issue size is ₹3,395.00 crores. Anthem Biosciences IPO offer consists entirely of 5.96 crore shares being sold by existing shareholders. The IPO price band is set for ₹540 to ₹570 per share, with a face value of ₹2 per share. It opens for subscription on July 14, 2025 and closes on July 16, 2025. A minimum of 26 shares per application is applicable.

Company Background

Anthem Biosciences Limited was established in 2006 and is in the business of innovation and technology in the CRDMO sector, with fully integrated operations in drug discovery, development and manufacturing. The company is a services provider to new biotech firms and large pharmaceutical companies worldwide, across more than 44 countries, including the U.S., Europe and Japan.

Anthem Biosciences is engaged in the production of fermentation-based APIs, probiotics, enzymes, peptides, nutritional actives, vitamin analogues and biosimilars. Up to September 2024, the company was implementing 196 projects. Out of them, 170 projects were in the discovery phase and 13 projects were in commercial manufacturing. It is supported by a strong intellectual property (IP) portfolio, which consists of an Indian patent, seven overseas patents and 24 pending global patent applications.

Operations and Product Range

Facility and Production

Anthem Biosciences runs advanced research and manufacturing facilities that support the entire process from drug lifecycle, from discovery to commercial production. Its infrastructure allows it to offer complete solutions for both small molecules and biologics.

Brand and Market Presence

Anthem Biosciences has a strong foothold as a reliable partner for pharmaceutical and biotech companies worldwide, providing services and products across the U.S., Europe, Japan and other key markets. Its influence in the market is based on its innovation, quality and focus on customer needs.

Revenue Channels

Anthem Biosciences Limited makes money mainly through:

Contract Research and Development: Offering discovery and early-phase research services for global clients.

Commercial Manufacturing: Producing APIs and intermediates for commercial supply.

Specialty Ingredients: Supplying fermentation-based products, enzymes, peptides and nutritional actives.

Long-Term Partnerships: Creating recurring revenue with long-term clients in the pharmaceutical and biotech sectors.

Management & Shareholding

Promoters & Shareholding

The promoters of Anthem Biosciences Limited are Ajay Bhardwaj, Ganesh Sambasivam, K Ravindra Chandrappa and Ishaan Bhardwaj. Before the IPO, the promoters collectively owned 76.87% of the equity, which is expected to decrease to 74.68% after the issue.

Board Members

The board includes Managing Director Kunal Bhimji Patel and Full-time Director and Chairman Bhimji Nanji Patel. Independent directors Prasannakumar Baliram Gawde, Nayan Jagdishchandra Rawal and Jagruti Prashant Sheth also serve on the board.